View Financial HealthSyncom Formulations (India) 배당 및 자사주 매입배당 기준 점검 0/6Syncom Formulations (India) 현재 배당금을 지급하지 않습니다.핵심 정보0%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향0%최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹12.25, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 88% over the past three years.Reported Earnings • Feb 14Third quarter 2026 earnings released: EPS: ₹0.23 (vs ₹0.14 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.23 (up from ₹0.14 in 3Q 2025). Revenue: ₹1.21b (down 5.4% from 3Q 2025). Net income: ₹189.1m (up 45% from 3Q 2025). Profit margin: 16% (up from 10% in 3Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.분석 기사 • Feb 02Here's Why We Think Syncom Formulations (India) (NSE:SYNCOMF) Is Well Worth WatchingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Reported Earnings • Nov 13Second quarter 2026 earnings released: EPS: ₹0.18 (vs ₹0.16 in 2Q 2025)Second quarter 2026 results: EPS: ₹0.18 (up from ₹0.16 in 2Q 2025). Revenue: ₹1.27b (up 24% from 2Q 2025). Net income: ₹166.0m (up 49% from 2Q 2025). Profit margin: 13% (up from 11% in 2Q 2025). The increase in margin was driven by higher revenue.공시 • Oct 01Syncom Formulations (India) Limited Approves Appointment of Shri Ankit Kedarmal as Executive ChairmanSyncom Formulations (India) Limited at its AGM held on September 29, 2025, approved appointment of Shri Ankit Kedarmal as Executive Chairman and to approve the remuneration payable to him.공시 • Sep 04+ 2 more updatesSyncom Formulations (India) Limited to Report Q3, 2026 Results on Feb 14, 2026Syncom Formulations (India) Limited announced that they will report Q3, 2026 results on Feb 14, 2026공시 • Aug 11Syncom Formulations (India) Limited, Annual General Meeting, Sep 29, 2025Syncom Formulations (India) Limited, Annual General Meeting, Sep 29, 2025, at 14:00 Indian Standard Time.Reported Earnings • Aug 09First quarter 2026 earnings released: EPS: ₹0.21 (vs ₹0.11 in 1Q 2025)First quarter 2026 results: EPS: ₹0.21 (up from ₹0.11 in 1Q 2025). Revenue: ₹1.23b (up 41% from 1Q 2025). Net income: ₹157.5m (up 106% from 1Q 2025). Profit margin: 13% (up from 8.7% in 1Q 2025). The increase in margin was driven by higher revenue.공시 • Aug 08+ 1 more updateSyncom Formulations (India) Limited Announces CFO ChangesSyncom Formulations (India) Limited announced that at its board meeting held on August 08, 2025, noted and accepted the resignation of Shri Ankit Kedarnal Bankda from the position of Chief Financial Officer (CFO), with effect from the close of business hours on August 08, 2025. The company approved the appointment of Shri Rahul Vijay Bankda as Chief Financial Officer (CFO) of the Company, with effect from August 09, 2025.공시 • Aug 02Syncom Formulations (India) Limited to Report Q1, 2026 Results on Aug 08, 2025Syncom Formulations (India) Limited announced that they will report Q1, 2026 results on Aug 08, 2025New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • May 21Full year 2025 earnings released: EPS: ₹0.57 (vs ₹0.27 in FY 2024)Full year 2025 results: EPS: ₹0.57 (up from ₹0.27 in FY 2024). Revenue: ₹4.82b (up 83% from FY 2024). Net income: ₹494.3m (up 95% from FY 2024). Profit margin: 10% (in line with FY 2024).분석 기사 • May 19Syncom Formulations (India) Limited's (NSE:SYNCOMF) Business Is Trailing The Market But Its Shares Aren'tWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") below 27x, you may consider Syncom...Valuation Update With 7 Day Price Move • May 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹17.49, the stock trades at a trailing P/E ratio of 42x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 31% over the past year.공시 • May 13Syncom Formulations (India) Limited to Report Q4, 2025 Results on May 19, 2025Syncom Formulations (India) Limited announced that they will report Q4, 2025 results on May 19, 2025Valuation Update With 7 Day Price Move • Mar 24Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹18.24, the stock trades at a trailing P/E ratio of 43.8x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 53% over the past year.Valuation Update With 7 Day Price Move • Mar 10Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹17.11, the stock trades at a trailing P/E ratio of 41.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 29% over the past year.분석 기사 • Mar 08Should You Be Adding Syncom Formulations (India) (NSE:SYNCOMF) To Your Watchlist Today?It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Reported Earnings • Feb 11Third quarter 2025 earnings released: EPS: ₹0.14 (vs ₹0.09 in 3Q 2024)Third quarter 2025 results: EPS: ₹0.14 (up from ₹0.09 in 3Q 2024). Revenue: ₹1.32b (up 102% from 3Q 2024). Net income: ₹130.0m (up 86% from 3Q 2024). Profit margin: 9.9% (in line with 3Q 2024).공시 • Feb 03Syncom Formulations (India) Limited to Report Q3, 2025 Results on Feb 12, 2025Syncom Formulations (India) Limited announced that they will report Q3, 2025 results on Feb 12, 2025분석 기사 • Jan 11Does Syncom Formulations (India) (NSE:SYNCOMF) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Dec 10Getting In Cheap On Syncom Formulations (India) Limited (NSE:SYNCOMF) Is UnlikelyWith a price-to-earnings (or "P/E") ratio of 67x Syncom Formulations (India) Limited ( NSE:SYNCOMF ) may be sending...Reported Earnings • Nov 12Second quarter 2025 earnings released: EPS: ₹0.16 (vs ₹0.08 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.16 (up from ₹0.08 in 2Q 2024). Revenue: ₹1.06b (up 67% from 2Q 2024). Net income: ₹111.1m (up 71% from 2Q 2024). Profit margin: 10% (in line with 2Q 2024).공시 • Nov 05Syncom Formulations (India) Limited to Report Q2, 2025 Results on Nov 11, 2024Syncom Formulations (India) Limited announced that they will report Q2, 2025 results on Nov 11, 2024Valuation Update With 7 Day Price Move • Sep 19Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹22.28, the stock trades at a trailing P/E ratio of 73.2x. Average trailing P/E is 42x in the Pharmaceuticals industry in India. Total returns to shareholders of 162% over the past year.New Risk • Sep 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.분석 기사 • Aug 30Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With EarningsSyncom Formulations (India) Limited ( NSE:SYNCOMF ) shares have continued their recent momentum with a 27% gain in the...Valuation Update With 7 Day Price Move • Aug 21Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹19.07, the stock trades at a trailing P/E ratio of 62.9x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 112% over the past year.공시 • Aug 13Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2024Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2024, at 14:00 Indian Standard Time.Reported Earnings • Aug 13First quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.07 in 1Q 2024)First quarter 2025 results: EPS: ₹0.11 (up from ₹0.07 in 1Q 2024). Revenue: ₹885.9m (up 48% from 1Q 2024). Net income: ₹76.3m (up 74% from 1Q 2024). Profit margin: 8.6% (up from 7.3% in 1Q 2024). The increase in margin was driven by higher revenue.공시 • Aug 02Syncom Formulations (India) Limited to Report Q1, 2025 Results on Aug 12, 2024Syncom Formulations (India) Limited announced that they will report Q1, 2025 results on Aug 12, 2024분석 기사 • Jul 16Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With EarningsSyncom Formulations (India) Limited ( NSE:SYNCOMF ) shareholders have had their patience rewarded with a 27% share...Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹16.01, the stock trades at a trailing P/E ratio of 59.5x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 112% over the past year.Reported Earnings • May 19Full year 2024 earnings released: EPS: ₹0.34 (vs ₹0.22 in FY 2023)Full year 2024 results: EPS: ₹0.34 (up from ₹0.22 in FY 2023). Revenue: ₹2.77b (up 24% from FY 2023). Net income: ₹253.1m (up 26% from FY 2023). Profit margin: 9.1% (up from 8.9% in FY 2023). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹12.85, the stock trades at a trailing P/E ratio of 46x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 96% over the past year.공시 • Mar 29Syncom Formulations (India) Limited Announces Board ChangesSyncom Formulations (India) Limited announced that tenure completion of Shri Vinod Kumar Kabra, Shri Krishna Das Neema and Shri Praveen Jindal Independent Director(s) of the Company appointed w.e.f., 1 April, 2014 for a tenure of five (5) year and further were re-appointed w.e.f. 1 April, 2019 for further tenure of five (5) year in the category of Non-Executive Independent Directors of the company w.e.f. close of working hour of 31 March, 2024.분석 기사 • Mar 21Some Syncom Formulations (India) Limited (NSE:SYNCOMF) Shareholders Look For Exit As Shares Take 28% PoundingSyncom Formulations (India) Limited ( NSE:SYNCOMF ) shares have had a horrible month, losing 28% after a relatively...Reported Earnings • Feb 15Third quarter 2024 earnings released: EPS: ₹0.09 (vs ₹0.06 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.09 (up from ₹0.06 in 3Q 2023). Revenue: ₹696.9m (up 22% from 3Q 2023). Net income: ₹70.0m (up 69% from 3Q 2023). Profit margin: 10.0% (up from 7.2% in 3Q 2023). The increase in margin was driven by higher revenue.분석 기사 • Dec 29Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With EarningsDespite an already strong run, Syncom Formulations (India) Limited ( NSE:SYNCOMF ) shares have been powering on, with a...Valuation Update With 7 Day Price Move • Dec 26Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹14.15, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 55% over the past year.Valuation Update With 7 Day Price Move • Nov 23Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹12.65, the stock trades at a trailing P/E ratio of 50.6x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 62% over the past year.Reported Earnings • Nov 11Second quarter 2024 earnings released: EPS: ₹0.08 (vs ₹0.06 in 2Q 2023)Second quarter 2024 results: EPS: ₹0.08 (up from ₹0.06 in 2Q 2023). Revenue: ₹678.4m (up 25% from 2Q 2023). Net income: ₹65.1m (up 81% from 2Q 2023). Profit margin: 9.6% (up from 6.6% in 2Q 2023). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Nov 09Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹10.30, the stock trades at a trailing P/E ratio of 47x. Average trailing P/E is 31x in the Pharmaceuticals industry in India.공시 • Sep 05+ 2 more updatesSyncom Formulations (India) Limited to Report Q3, 2024 Results on Feb 14, 2024Syncom Formulations (India) Limited announced that they will report Q3, 2024 results on Feb 14, 2024공시 • Aug 15Syncom Formulations (India) Limited, Annual General Meeting, Sep 26, 2023Syncom Formulations (India) Limited, Annual General Meeting, Sep 26, 2023, at 15:00 Indian Standard Time.Reported Earnings • Aug 15First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: ₹0.07. Revenue: ₹617.1m (up 20% from 1Q 2023). Net income: ₹44.0m (up 14% from 1Q 2023). Profit margin: 7.1% (down from 7.5% in 1Q 2023). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Aug 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹9.25, the stock trades at a trailing P/E ratio of 43.4x. Average trailing P/E is 30x in the Pharmaceuticals industry in India.공시 • Aug 04Syncom Formulations (India) Limited to Report Q1, 2024 Results on Aug 14, 2023Syncom Formulations (India) Limited announced that they will report Q1, 2024 results on Aug 14, 2023Reported Earnings • Jun 02Full year 2023 earnings released: EPS: ₹0.24 (vs ₹0.24 in FY 2022)Full year 2023 results: EPS: ₹0.24. Revenue: ₹2.39b (up 8.7% from FY 2022). Net income: ₹200.7m (up 1.4% from FY 2022). Profit margin: 8.4% (down from 9.0% in FY 2022). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Mar 28Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹5.00, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in India.Reported Earnings • Feb 14Third quarter 2023 earnings released: EPS: ₹0.06 (vs ₹0.07 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.06. Revenue: ₹593.6m (up 3.7% from 3Q 2022). Net income: ₹41.4m (up 3.3% from 3Q 2022). Profit margin: 7.0% (in line with 3Q 2022).공시 • Feb 02Syncom Formulations (India) Limited to Report Q3, 2023 Results on Feb 13, 2023Syncom Formulations (India) Limited announced that they will report Q3, 2023 results on Feb 13, 2023분석 기사 • Dec 27Syncom Formulations (India) Limited's (NSE:SYNCOMF) Shares Climb 26% But Its Business Is Yet to Catch UpSyncom Formulations (India) Limited ( NSE:SYNCOMF ) shareholders would be excited to see that the share price has had a...Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₹9.70, the stock trades at a trailing P/E ratio of 56.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India.Board Change • Nov 21Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. No experienced directors. 6 highly experienced directors. Additional Non-Executive Independent Woman Director Ruchi Jindal was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 SYNCOMF 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: SYNCOMF 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Syncom Formulations (India) 배당 수익률 vs 시장SYNCOMF의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (SYNCOMF)0%시장 하위 25% (IN)0.3%시장 상위 25% (IN)1.5%업계 평균 (Pharmaceuticals)0.7%분석가 예측 (SYNCOMF) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 SYNCOMF 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 SYNCOMF 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: SYNCOMF Indian 시장에서 주목할만한 배당금을 지급하지 않습니다.주주 현금 배당현금 흐름 범위: SYNCOMF 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIN 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 06:43종가2026/05/22 00:00수익2025/12/31연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Syncom Formulations (India) Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹12.25, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 88% over the past three years.
Reported Earnings • Feb 14Third quarter 2026 earnings released: EPS: ₹0.23 (vs ₹0.14 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.23 (up from ₹0.14 in 3Q 2025). Revenue: ₹1.21b (down 5.4% from 3Q 2025). Net income: ₹189.1m (up 45% from 3Q 2025). Profit margin: 16% (up from 10% in 3Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.
분석 기사 • Feb 02Here's Why We Think Syncom Formulations (India) (NSE:SYNCOMF) Is Well Worth WatchingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Reported Earnings • Nov 13Second quarter 2026 earnings released: EPS: ₹0.18 (vs ₹0.16 in 2Q 2025)Second quarter 2026 results: EPS: ₹0.18 (up from ₹0.16 in 2Q 2025). Revenue: ₹1.27b (up 24% from 2Q 2025). Net income: ₹166.0m (up 49% from 2Q 2025). Profit margin: 13% (up from 11% in 2Q 2025). The increase in margin was driven by higher revenue.
공시 • Oct 01Syncom Formulations (India) Limited Approves Appointment of Shri Ankit Kedarmal as Executive ChairmanSyncom Formulations (India) Limited at its AGM held on September 29, 2025, approved appointment of Shri Ankit Kedarmal as Executive Chairman and to approve the remuneration payable to him.
공시 • Sep 04+ 2 more updatesSyncom Formulations (India) Limited to Report Q3, 2026 Results on Feb 14, 2026Syncom Formulations (India) Limited announced that they will report Q3, 2026 results on Feb 14, 2026
공시 • Aug 11Syncom Formulations (India) Limited, Annual General Meeting, Sep 29, 2025Syncom Formulations (India) Limited, Annual General Meeting, Sep 29, 2025, at 14:00 Indian Standard Time.
Reported Earnings • Aug 09First quarter 2026 earnings released: EPS: ₹0.21 (vs ₹0.11 in 1Q 2025)First quarter 2026 results: EPS: ₹0.21 (up from ₹0.11 in 1Q 2025). Revenue: ₹1.23b (up 41% from 1Q 2025). Net income: ₹157.5m (up 106% from 1Q 2025). Profit margin: 13% (up from 8.7% in 1Q 2025). The increase in margin was driven by higher revenue.
공시 • Aug 08+ 1 more updateSyncom Formulations (India) Limited Announces CFO ChangesSyncom Formulations (India) Limited announced that at its board meeting held on August 08, 2025, noted and accepted the resignation of Shri Ankit Kedarnal Bankda from the position of Chief Financial Officer (CFO), with effect from the close of business hours on August 08, 2025. The company approved the appointment of Shri Rahul Vijay Bankda as Chief Financial Officer (CFO) of the Company, with effect from August 09, 2025.
공시 • Aug 02Syncom Formulations (India) Limited to Report Q1, 2026 Results on Aug 08, 2025Syncom Formulations (India) Limited announced that they will report Q1, 2026 results on Aug 08, 2025
New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • May 21Full year 2025 earnings released: EPS: ₹0.57 (vs ₹0.27 in FY 2024)Full year 2025 results: EPS: ₹0.57 (up from ₹0.27 in FY 2024). Revenue: ₹4.82b (up 83% from FY 2024). Net income: ₹494.3m (up 95% from FY 2024). Profit margin: 10% (in line with FY 2024).
분석 기사 • May 19Syncom Formulations (India) Limited's (NSE:SYNCOMF) Business Is Trailing The Market But Its Shares Aren'tWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") below 27x, you may consider Syncom...
Valuation Update With 7 Day Price Move • May 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹17.49, the stock trades at a trailing P/E ratio of 42x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 31% over the past year.
공시 • May 13Syncom Formulations (India) Limited to Report Q4, 2025 Results on May 19, 2025Syncom Formulations (India) Limited announced that they will report Q4, 2025 results on May 19, 2025
Valuation Update With 7 Day Price Move • Mar 24Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹18.24, the stock trades at a trailing P/E ratio of 43.8x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 53% over the past year.
Valuation Update With 7 Day Price Move • Mar 10Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹17.11, the stock trades at a trailing P/E ratio of 41.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 29% over the past year.
분석 기사 • Mar 08Should You Be Adding Syncom Formulations (India) (NSE:SYNCOMF) To Your Watchlist Today?It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Reported Earnings • Feb 11Third quarter 2025 earnings released: EPS: ₹0.14 (vs ₹0.09 in 3Q 2024)Third quarter 2025 results: EPS: ₹0.14 (up from ₹0.09 in 3Q 2024). Revenue: ₹1.32b (up 102% from 3Q 2024). Net income: ₹130.0m (up 86% from 3Q 2024). Profit margin: 9.9% (in line with 3Q 2024).
공시 • Feb 03Syncom Formulations (India) Limited to Report Q3, 2025 Results on Feb 12, 2025Syncom Formulations (India) Limited announced that they will report Q3, 2025 results on Feb 12, 2025
분석 기사 • Jan 11Does Syncom Formulations (India) (NSE:SYNCOMF) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
분석 기사 • Dec 10Getting In Cheap On Syncom Formulations (India) Limited (NSE:SYNCOMF) Is UnlikelyWith a price-to-earnings (or "P/E") ratio of 67x Syncom Formulations (India) Limited ( NSE:SYNCOMF ) may be sending...
Reported Earnings • Nov 12Second quarter 2025 earnings released: EPS: ₹0.16 (vs ₹0.08 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.16 (up from ₹0.08 in 2Q 2024). Revenue: ₹1.06b (up 67% from 2Q 2024). Net income: ₹111.1m (up 71% from 2Q 2024). Profit margin: 10% (in line with 2Q 2024).
공시 • Nov 05Syncom Formulations (India) Limited to Report Q2, 2025 Results on Nov 11, 2024Syncom Formulations (India) Limited announced that they will report Q2, 2025 results on Nov 11, 2024
Valuation Update With 7 Day Price Move • Sep 19Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹22.28, the stock trades at a trailing P/E ratio of 73.2x. Average trailing P/E is 42x in the Pharmaceuticals industry in India. Total returns to shareholders of 162% over the past year.
New Risk • Sep 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
분석 기사 • Aug 30Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With EarningsSyncom Formulations (India) Limited ( NSE:SYNCOMF ) shares have continued their recent momentum with a 27% gain in the...
Valuation Update With 7 Day Price Move • Aug 21Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹19.07, the stock trades at a trailing P/E ratio of 62.9x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 112% over the past year.
공시 • Aug 13Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2024Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2024, at 14:00 Indian Standard Time.
Reported Earnings • Aug 13First quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.07 in 1Q 2024)First quarter 2025 results: EPS: ₹0.11 (up from ₹0.07 in 1Q 2024). Revenue: ₹885.9m (up 48% from 1Q 2024). Net income: ₹76.3m (up 74% from 1Q 2024). Profit margin: 8.6% (up from 7.3% in 1Q 2024). The increase in margin was driven by higher revenue.
공시 • Aug 02Syncom Formulations (India) Limited to Report Q1, 2025 Results on Aug 12, 2024Syncom Formulations (India) Limited announced that they will report Q1, 2025 results on Aug 12, 2024
분석 기사 • Jul 16Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With EarningsSyncom Formulations (India) Limited ( NSE:SYNCOMF ) shareholders have had their patience rewarded with a 27% share...
Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹16.01, the stock trades at a trailing P/E ratio of 59.5x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 112% over the past year.
Reported Earnings • May 19Full year 2024 earnings released: EPS: ₹0.34 (vs ₹0.22 in FY 2023)Full year 2024 results: EPS: ₹0.34 (up from ₹0.22 in FY 2023). Revenue: ₹2.77b (up 24% from FY 2023). Net income: ₹253.1m (up 26% from FY 2023). Profit margin: 9.1% (up from 8.9% in FY 2023). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹12.85, the stock trades at a trailing P/E ratio of 46x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 96% over the past year.
공시 • Mar 29Syncom Formulations (India) Limited Announces Board ChangesSyncom Formulations (India) Limited announced that tenure completion of Shri Vinod Kumar Kabra, Shri Krishna Das Neema and Shri Praveen Jindal Independent Director(s) of the Company appointed w.e.f., 1 April, 2014 for a tenure of five (5) year and further were re-appointed w.e.f. 1 April, 2019 for further tenure of five (5) year in the category of Non-Executive Independent Directors of the company w.e.f. close of working hour of 31 March, 2024.
분석 기사 • Mar 21Some Syncom Formulations (India) Limited (NSE:SYNCOMF) Shareholders Look For Exit As Shares Take 28% PoundingSyncom Formulations (India) Limited ( NSE:SYNCOMF ) shares have had a horrible month, losing 28% after a relatively...
Reported Earnings • Feb 15Third quarter 2024 earnings released: EPS: ₹0.09 (vs ₹0.06 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.09 (up from ₹0.06 in 3Q 2023). Revenue: ₹696.9m (up 22% from 3Q 2023). Net income: ₹70.0m (up 69% from 3Q 2023). Profit margin: 10.0% (up from 7.2% in 3Q 2023). The increase in margin was driven by higher revenue.
분석 기사 • Dec 29Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With EarningsDespite an already strong run, Syncom Formulations (India) Limited ( NSE:SYNCOMF ) shares have been powering on, with a...
Valuation Update With 7 Day Price Move • Dec 26Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹14.15, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 55% over the past year.
Valuation Update With 7 Day Price Move • Nov 23Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹12.65, the stock trades at a trailing P/E ratio of 50.6x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 62% over the past year.
Reported Earnings • Nov 11Second quarter 2024 earnings released: EPS: ₹0.08 (vs ₹0.06 in 2Q 2023)Second quarter 2024 results: EPS: ₹0.08 (up from ₹0.06 in 2Q 2023). Revenue: ₹678.4m (up 25% from 2Q 2023). Net income: ₹65.1m (up 81% from 2Q 2023). Profit margin: 9.6% (up from 6.6% in 2Q 2023). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Nov 09Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹10.30, the stock trades at a trailing P/E ratio of 47x. Average trailing P/E is 31x in the Pharmaceuticals industry in India.
공시 • Sep 05+ 2 more updatesSyncom Formulations (India) Limited to Report Q3, 2024 Results on Feb 14, 2024Syncom Formulations (India) Limited announced that they will report Q3, 2024 results on Feb 14, 2024
공시 • Aug 15Syncom Formulations (India) Limited, Annual General Meeting, Sep 26, 2023Syncom Formulations (India) Limited, Annual General Meeting, Sep 26, 2023, at 15:00 Indian Standard Time.
Reported Earnings • Aug 15First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: ₹0.07. Revenue: ₹617.1m (up 20% from 1Q 2023). Net income: ₹44.0m (up 14% from 1Q 2023). Profit margin: 7.1% (down from 7.5% in 1Q 2023). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Aug 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹9.25, the stock trades at a trailing P/E ratio of 43.4x. Average trailing P/E is 30x in the Pharmaceuticals industry in India.
공시 • Aug 04Syncom Formulations (India) Limited to Report Q1, 2024 Results on Aug 14, 2023Syncom Formulations (India) Limited announced that they will report Q1, 2024 results on Aug 14, 2023
Reported Earnings • Jun 02Full year 2023 earnings released: EPS: ₹0.24 (vs ₹0.24 in FY 2022)Full year 2023 results: EPS: ₹0.24. Revenue: ₹2.39b (up 8.7% from FY 2022). Net income: ₹200.7m (up 1.4% from FY 2022). Profit margin: 8.4% (down from 9.0% in FY 2022). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Mar 28Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹5.00, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in India.
Reported Earnings • Feb 14Third quarter 2023 earnings released: EPS: ₹0.06 (vs ₹0.07 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.06. Revenue: ₹593.6m (up 3.7% from 3Q 2022). Net income: ₹41.4m (up 3.3% from 3Q 2022). Profit margin: 7.0% (in line with 3Q 2022).
공시 • Feb 02Syncom Formulations (India) Limited to Report Q3, 2023 Results on Feb 13, 2023Syncom Formulations (India) Limited announced that they will report Q3, 2023 results on Feb 13, 2023
분석 기사 • Dec 27Syncom Formulations (India) Limited's (NSE:SYNCOMF) Shares Climb 26% But Its Business Is Yet to Catch UpSyncom Formulations (India) Limited ( NSE:SYNCOMF ) shareholders would be excited to see that the share price has had a...
Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₹9.70, the stock trades at a trailing P/E ratio of 56.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India.
Board Change • Nov 21Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. No experienced directors. 6 highly experienced directors. Additional Non-Executive Independent Woman Director Ruchi Jindal was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.